HR+/ HER2-VE Breast Cancer - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “HR+/ HER2-VE Breast Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HR+/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
HR+/ HER2-VE Breast Cancer: Overview
HR+ breast cancers are those that express estrogen receptors (ER) or progesterone receptors (PR) or both. These tumors account for 70–80% of all breast cancers. These hormone-dependent cancers can often be treated successfully with a variety of drugs that modulate ER or reduce estrogen.
HER2 is short for human epidermal growth factor receptor. HER2 is sometimes called ERBB2, which stands for Erb-B2 receptor tyrosine kinase. HER2 is a gene that produces HER2 proteins, or receptors. If breast cancer cells don’t have abnormal levels of HER2 proteins, the breast cancer is considered HER2-negative.
Report Highlights
This segment of the HR+/ HER2-VE Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HR+/ HER2-VE Breast Cancer Emerging Drugs
Further product details are provided in the report……..
HR+/ HER2-VE Breast Cancer: Therapeutic Assessment
This segment of the report provides insights about the different HR+/ HER2-VE Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:
HR+/ HER2-VE Breast Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses HR+/ HER2-VE Breast Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HR+/ HER2-VE Breast Cancer drugs.
HR+/ HER2-VE Breast Cancer Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “HR+/ HER2-VE Breast Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HR+/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
HR+/ HER2-VE Breast Cancer: Overview
HR+ breast cancers are those that express estrogen receptors (ER) or progesterone receptors (PR) or both. These tumors account for 70–80% of all breast cancers. These hormone-dependent cancers can often be treated successfully with a variety of drugs that modulate ER or reduce estrogen.
HER2 is short for human epidermal growth factor receptor. HER2 is sometimes called ERBB2, which stands for Erb-B2 receptor tyrosine kinase. HER2 is a gene that produces HER2 proteins, or receptors. If breast cancer cells don’t have abnormal levels of HER2 proteins, the breast cancer is considered HER2-negative.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence HR+/ HER2-VE Breast Cancer R&D. The therapies under development are focused on novel approaches for HR+/ HER2-VE Breast Cancer.
This segment of the HR+/ HER2-VE Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HR+/ HER2-VE Breast Cancer Emerging Drugs
- AZD9833: Astrazeneca
- BGB-290: BeiGene
Further product details are provided in the report……..
HR+/ HER2-VE Breast Cancer: Therapeutic Assessment
This segment of the report provides insights about the different HR+/ HER2-VE Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on HR+/ HER2-VE Breast Cancer
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
HR+/ HER2-VE Breast Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses HR+/ HER2-VE Breast Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HR+/ HER2-VE Breast Cancer drugs.
HR+/ HER2-VE Breast Cancer Report Insights
- HR+/ HER2-VE Breast Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing HR+/ HER2-VE Breast Cancer drugs?
- How many HR+/ HER2-VE Breast Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for HR+/ HER2-VE Breast Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HR+/ HER2-VE Breast Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for HR+/ HER2-VE Breast Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- BeiGene
- H3 Biomedicine
- AstraZeneca
- Olema Pharmaceuticals
- CytomX Therapeutics
- Roche
- G1 Therapeutics
- Sanofi
- Jiangsu HengRui Medicine
- BGB-290
- H3B-6545
- AZD9833
- OP-1250
- CX-2009
- RG6171
- Rintodestrant
- Amcenestrant
- SHR6390
Introduction
Executive Summary
HR+/ HER2-VE Breast Cancer: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
AZD9833: Astrazeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
BGB-290: BeiGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
OP-1250: Olema Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
HR+/ HER2-VE Breast Cancer Key Companies
HR+/ HER2-VE Breast Cancer Key Products
HR+/ HER2-VE Breast Cancer- Unmet Needs
HR+/ HER2-VE Breast Cancer- Market Drivers and Barriers
HR+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion
HR+/ HER2-VE Breast Cancer Analyst Views
HR+/ HER2-VE Breast Cancer Key Companies
Appendix
Executive Summary
HR+/ HER2-VE Breast Cancer: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
AZD9833: Astrazeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
BGB-290: BeiGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
OP-1250: Olema Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
HR+/ HER2-VE Breast Cancer Key Companies
HR+/ HER2-VE Breast Cancer Key Products
HR+/ HER2-VE Breast Cancer- Unmet Needs
HR+/ HER2-VE Breast Cancer- Market Drivers and Barriers
HR+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion
HR+/ HER2-VE Breast Cancer Analyst Views
HR+/ HER2-VE Breast Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for HR+/ HER2-VE Breast Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for HR+/ HER2-VE Breast Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for HR+/ HER2-VE Breast Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for HR+/ HER2-VE Breast Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
